$INSM

Flammer Martina M.D. sold $262K of INSM

Flammer Martina M.D. (Chief Medical Officer) sold 2,566 shares of INSMED Inc (INSM) at $102.27 ($0.26M total) on 2026-06-03 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Flammer Martina M.D.
Published Jun 5, 2026, 8:11 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 5, 2026, 8:14 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$INSM
Neutral
medium confidence
Mentioned
$INSM
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$INSMNeutralLow
01

Why it matters

This provides a datapoint on insider activity but does not include new company fundamentals (no earnings, trial, guidance, or deal).

02

Market read

Traders may monitor insider activity, but the 10b5-1 designation makes the information less likely to drive a durable repricing.

03

What to watch

The filing does not indicate whether other insiders or institutions are changing positions; it’s one officer’s transaction size and timing.

Relevance 6/10Novelty 3/10Timing: Filed June 5; sale executed June 3 under a 10b5-1 plan.

Background

The article is an SEC Form 4 insider transaction disclosure for INSMED, reported by the company’s Chief Medical Officer.

Company-level read

Ticker impact

$INSMNeutralMedium confidence
Context

INSMED CMO Flammer Martina sold 2,566 shares (~$262.4K) via an open-market transaction under a pre-arranged 10b5-1 plan.

Expected impact

Limited near-term impact; any reaction is likely sentiment-driven and short-lived.

Evidence & confidence

The filing is a routine insider transaction with explicit 10b5-1 pre-arrangement, reducing the probability it reflects new negative information.

Market effects

No clear sector read-through from a single 10b5-1 insider sale.

None indicated.

None indicated.

Counterpoint

Because the sale is pre-arranged under 10b5-1, it may reflect scheduled liquidity needs rather than a view on INSM’s prospects.

Key entities

  • INSMED Inc

    Public company whose shares were sold by an officer under a 10b5-1 plan.

  • Flammer Martina M.D.

    Chief Medical Officer who executed the open-market sale.

Related articles

$INSMMed

Insmed Q2 Earnings Call Highlights

Insmed (INSM) reported Q2 call highlights. It narrowed BRINSUPRI gross-to-net guidance to mid-to-high 20% and raised global peak sales to over $7B. It expects ARIKAYCE expansion filings in the U.S. and Japan, with Japan application in 2H26. TPIP peak sales estimate rose to over $6B. Cash was about $1.2B; it targets cash-flow positivity in 2027.